Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

Andre Goy, MD
Published: Wednesday, Jul 25, 2018



Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Physicians have made significant progress in the treatment of patients with MCL, says Goy, but states that there is a disconnect between what is seen in clinical trials and the real world. The outcome with standard therapy is very dismal, so there has been a great emphasis on research in MCL.

Over the last 3 decades, the progression of treatment improved the median overall survival (OS) from 2.5 years to greater than 12 to 13 years, says Goy. Care has also extended beyond management, as there are patients with MCL who can be cured, explains Goy. This applies to younger patients who have minimal residual disease negativity after high-dose therapy and transplant as well as elderly patients who achieve a complete remission, receive maintenance rituximab (Rituxan), and demonstrate dramatic improvement in progression-free survival and OS.

Research efforts are focused on improving the different phases of treatment, states Goy. Although clinical trials have demonstrated a benefit with these approaches, the median survival in the real world ranges from 3 to 5 years.


Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Physicians have made significant progress in the treatment of patients with MCL, says Goy, but states that there is a disconnect between what is seen in clinical trials and the real world. The outcome with standard therapy is very dismal, so there has been a great emphasis on research in MCL.

Over the last 3 decades, the progression of treatment improved the median overall survival (OS) from 2.5 years to greater than 12 to 13 years, says Goy. Care has also extended beyond management, as there are patients with MCL who can be cured, explains Goy. This applies to younger patients who have minimal residual disease negativity after high-dose therapy and transplant as well as elderly patients who achieve a complete remission, receive maintenance rituximab (Rituxan), and demonstrate dramatic improvement in progression-free survival and OS.

Research efforts are focused on improving the different phases of treatment, states Goy. Although clinical trials have demonstrated a benefit with these approaches, the median survival in the real world ranges from 3 to 5 years.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x